Pharmaceuticals

Drug Development Drug Safety Weight Loss Drugs Weight Loss Clinical Trials Drug Pricing Drug Approval Medications Drug Regulation Over-the-Counter Medications

NCI Pursues Preclinical Test of Ivermectin’s Anti-Cancer Activity

The move, disclosed by director Anthony Letai, has drawn internal alarm over spending on a drug with no credible clinical benefit.

Takeda Strikes Multi-Year AI Drug Discovery Pact With Iambic Worth Over $1.7 Billion

Lilly and Innovent Forge Territory-Split Cancer and Immunology Alliance

Vistagen Investors Urged to Seek Lead Plaintiff Role in Securities Suit as March 16 Deadline Nears

Novo’s New GLP‑1 Pill Tests Lilly’s Lead as Investors Eye Pfizer’s Cheaper Shares

GLP-1 Weight-Loss Boom Triggers Safety Warnings and New Oversight

Merck Beats Q4 Forecasts as 2026 Guidance Trails Estimates on Patent Losses

AstraZeneca Strikes $1.2 Billion CSPC Pact for Once‑Monthly Obesity and Diabetes Programs

Eli Lilly Picks Lehigh Valley for $3.5 Billion Plant to Make Next-Gen Weight-Loss Drugs

HHS Rescinds Biden-Era Pharmacy Guidance on Reproductive-Health Drugs as DOJ Seeks Pause in Mifepristone Case

GLP-1 Weight-Loss Push Intensifies as Novo Leads Ads and Wegovy Pill Drives Telehealth Uptake

Insilico, Qilu Strike Near-$120 Million AI Drug Discovery Pact for Cardiometabolic Therapies

Wall Street Sees 175% Upside for Viking Therapeutics on Obesity Drug Bet

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

CPSC Recalls Two Amazon Hair Growth Serums Over Child Safety Risk

Weight-Loss Pills Could Trim Airline Fuel Costs, Jefferies Says

FDA Delays Two Drugs in National Priority Voucher Program After Safety, Efficacy Flags

Strive Compounding Sues Lilly and Novo, Alleging Antitrust Push to Block Compounded GLP-1s

U.S. Health Spending Hits $5.3 Trillion in 2024 on Utilization Surge, CMS Says

EMA and FDA Unveil Joint Principles for AI in Drug Development